| Ticker Details |
Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company. The company operates in one reportable segment: the research, manufacture, and distribution of patient-specific, used in the treatment of specific diseases.
|
| IPO Date: |
November 25, 2014 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$1.77B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.58 | 2.54%
|
| Avg Daily Range (30 D): |
$0.92 | 2.58%
|
| Avg Daily Range (90 D): |
$0.75 | 2.13%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.47M |
| Avg Daily Volume (30 D): |
.47M |
| Avg Daily Volume (90 D): |
.46M |
| Trade Size |
| Avg Trade Size (Sh.): |
96 |
| Avg Trade Size (Sh.) (30 D): |
52 |
| Avg Trade Size (Sh.) (90 D): |
53 |
| Institutional Trades |
| Total Institutional Trades: |
3,179 |
| Avg Institutional Trade: |
$2.51M |
| Avg Institutional Trade (30 D): |
$2.81M |
| Avg Institutional Trade (90 D): |
$2.6M |
| Avg Institutional Trade Volume: |
.08M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$3M |
| Avg Closing Trade (30 D): |
$3.41M |
| Avg Closing Trade (90 D): |
$3.43M |
| Avg Closing Volume: |
90.55K |
|
|
| Financials |
| |
TTM |
Q1 2026 |
Q4 2025 |
|
Basic EPS
|
$.43
|
$-.12
|
$.46
|
|
Diluted EPS
|
$.42
|
$-.12
|
$.45
|
|
Revenue
|
$292.09M
|
$68.43M
|
$92.92M
|
|
Gross Profit
|
$218.59M
|
$49.27M
|
$73.13M
|
|
Net Income / Loss
|
$21.46M
|
$-6.3M
|
$23.24M
|
|
Operating Income / Loss
|
$15.77M
|
$-8.06M
|
$22.42M
|
|
Cost of Revenue
|
$73.49M
|
$19.16M
|
$19.79M
|
|
Net Cash Flow
|
$29.59M
|
$9.2M
|
$-.31M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Oct 16, 2013
|
1:20
|
|
Feb 18, 2010
|
1:8
|
|
|
|
